Econ Financial Services Corp Sells 8,757 Shares of Merck & Co., Inc. $MRK

Econ Financial Services Corp lowered its stake in Merck & Co., Inc. (NYSE:MRK) by 36.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,485 shares of the company’s stock after selling 8,757 shares during the period. Econ Financial Services Corp’s holdings in Merck & Co., Inc. were worth $1,630,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Community Financial Services Group LLC lifted its position in Merck & Co., Inc. by 1.3% in the fourth quarter. Community Financial Services Group LLC now owns 29,591 shares of the company’s stock worth $3,115,000 after buying an additional 390 shares during the last quarter. LeConte Wealth Management LLC increased its position in Merck & Co., Inc. by 11.1% during the fourth quarter. LeConte Wealth Management LLC now owns 3,087 shares of the company’s stock valued at $325,000 after acquiring an additional 309 shares during the last quarter. Nisa Investment Advisors LLC increased its position in Merck & Co., Inc. by 4.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 711,119 shares of the company’s stock valued at $75,434,000 after acquiring an additional 27,207 shares during the last quarter. Santori & Peters Inc. bought a new position in Merck & Co., Inc. during the fourth quarter valued at $247,000. Finally, Meyer Handelman Co. increased its position in Merck & Co., Inc. by 0.3% during the fourth quarter. Meyer Handelman Co. now owns 378,287 shares of the company’s stock valued at $39,818,000 after acquiring an additional 1,114 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MRK has been the subject of several analyst reports. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Barclays began coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Merck & Co., Inc. in a research report on Monday, December 29th. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Finally, TD Cowen boosted their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Merck & Co., Inc. Stock Up 1.8%

Shares of MRK opened at $120.26 on Wednesday. The firm has a market capitalization of $297.34 billion, a P/E ratio of 16.52, a P/E/G ratio of 2.28 and a beta of 0.27. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The firm has a fifty day moving average price of $117.04 and a 200-day moving average price of $102.55.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same quarter last year, the firm posted $1.72 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities research analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Buying and Selling at Merck & Co., Inc.

In other news, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at approximately $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the sale, the executive vice president owned 160,174 shares of the company’s stock, valued at $19,368,240.08. The trade was a 19.05% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 320,176 shares of company stock valued at $38,281,735. 0.09% of the stock is owned by corporate insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck struck an R&D collaboration with Infinimmune to discover multiple human antibodies, a deal worth up to about $838 million in milestones — expands discovery engine with low upfront risk and broadens immunology/oncology pipeline. Infinimmune, Merck enter into antibody discovery pact
• Positive Sentiment: Late‑stage results: Merck reported an oral cholesterol drug reduced “bad” LDL cholesterol by ~64.6% in a Phase 3 trial — a potential next blockbuster and revenue driver if approved. Merck’s drug reduced bad cholesterol by 64.6% in late-stage trial
• Positive Sentiment: Clinical pipeline wins beyond cholesterol: coverage of WINREVAIR Phase 2 success in a tough heart‑failure segment highlights additional mid‑stage upside and may support expectations for future label expansions. How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment
• Positive Sentiment: Analyst support: Royal Bank of Canada reaffirmed an “outperform” rating and set a $142 price target, signaling analyst confidence in upside and reinforcing buy interest. Benzinga
• Positive Sentiment: M&A and portfolio building: Merck’s earlier ~$6.7B Terns acquisition and other strategic bets strengthen the oncology/precision‑medicine growth story and support longer‑term revenue visibility. Merck Just Made a Big Bet on a New Cancer Growth Engine
• Neutral Sentiment: Macro positioning: Barclays listed Merck among defensive stocks to consider amid market volatility — may attract safe‑haven flows but is a structural view rather than an immediate catalyst. Barclays names top 4 defensive stocks to weather global uncertainty
• Neutral Sentiment: Sector fund flows: Blackstone closed a record $6.3B life‑sciences fund, positive for biotech/medtech deal activity broadly but not an immediate company‑specific driver. Blackstone closes largest ever private funding investment round at $6.3bn
• Negative Sentiment: Broader market weakness and recent pullbacks: Merck shares dipped with the broader market correction recently, creating near‑term volatility and profit‑taking risk despite company‑specific positives. Merck (MRK) Dips More Than Broader Market: What You Should Know

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.